The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics
| Autor: | Bene Ekine-Afolabi, Sandra E. Sephton, Attia M. Elbehi, Cassandra Woolley, R.I. Anu, Elizabeth Cash, Victor C. Kok |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Circadian disruption Cancer Research Immune checkpoint inhibitors medicine.medical_treatment Circadian clock Review Immune checkpoint inhibitor lcsh:RC254-282 03 medical and health sciences Glucocorticoid 0302 clinical medicine Immune system Circadian Clocks Neoplasms Humans Clock gene Medicine Circadian rhythm Cancer business.industry Circadian Immuno-oncology Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease CLOCK 030104 developmental biology Oncology 030220 oncology & carcinogenesis business Neuroscience |
| Zdroj: | Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-14 (2021) Journal of Experimental & Clinical Cancer Research : CR |
| ISSN: | 1756-9966 |
| DOI: | 10.1186/s13046-021-01919-5 |
| Popis: | The circadian system temporally regulates physiology to maintain homeostasis. Co-opting and disrupting circadian signals appear to be distinct attributes that are functionally important for the development of a tumor and can enable or give rise to the hallmarks that tumors use to facilitate their initiation, growth and progression. Because circadian signals are also strong regulators of immune cell proliferation, trafficking and exhaustion states, they play a role in how tumors respond to immune-based cancer therapeutics. While immuno-oncology has heralded a paradigm shift in cancer therapeutics, greater accuracy is needed to increase our capability of predicting who will respond favorably to, or who is likely to experience the troubling adverse effects of, immunotherapy. Insights into circadian signals may further refine our understanding of biological determinants of response and help answer the fundamental question of whether certain perturbations in circadian signals interfere with the activity of immune checkpoint inhibitors. Here we review the body of literature highlighting circadian disruption as a cancer promoter and synthesize the burgeoning evidence suggesting circadian signals play a role in how tumors respond to immune-based anti-cancer therapeutics. The goal is to develop a framework to advance our understanding of the relationships between circadian markers, cancer biology, and immunotherapeutics. Bolstered by this new understanding, these relationships may then be pursued in future clinical studies to improve our ability to predict which patients will respond favorably to, and avoid the adverse effects of, traditional and immune-based cancer therapeutics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink